Ruth ORegan ABRCC

    Clinical Researchers Showcase Series - April 2015

    Translational Medicine Research:

 View from the Trenches Newsletter


Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more

from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Ruth O'Regan, M.D.
University of Wisconsin, Madison WI

ABRCC Investigator

Dr. Ruth O’Regan is the Division Head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health.


Dr. O’Regan is an internationally recognized breast-cancer physician and researcher with particular expertise on breast cancers that are resistant to current therapies.

A native of Dublin, Ireland, O’Regan previously was a professor of hematology and medical oncology at Emory University, where she held the Louisa and Rand Glenn Family Chair in Breast Cancer Research. Additionally, O’Regan was the medical director at Glenn Family Breast Center of Emory University, director of the Breast Cancer Translational Research Program at the Winship Cancer Institute, and chief of hematology and medical oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital.

In her dedication to training the next generation of physicians, O’Regan served as vice chair for educational affairs in the department of hematology and medical oncology and as director of the hematology/oncology fellowship program at Emory University.

With a highly active research program focused on identifying mechanisms of resistance to breast-cancer therapies and development of new therapies, O’Regan has been principal investigator for numerous grants and clinical trials.

Her research group has made significant discoveries about the role of the PI3 Kinase-mTOR pathway in triple-negative breast cancer, showing that mTOR inhibition can sensitize breast-cancer cells to upstream growth-factor inhibitors. These discoveries resulted in a novel clinical trial for patients with metastatic breast cancer.


About University of Wisconsin Carbone Cancer Center
UW Health consists of the academic health care entities of the University of Wisconsin-Madison: UW Medical Foundation, UW Hospital and Clinics and UW School of Medicine and Public Health. UW Health is also home to American Family Children's Hospital and UW Carbone Cancer Center. Our expert doctors are at the forefront of research, developing new treatments and training the next generation of physicians. This network provides access to more than 1,200 primary and specialty care physicians who are leaders in their fields, as well as the opportunity to be treated at University of Wisconsin Hospital and Clinics, frequently cited in published rankings of the finest academic medical centers. Learn more at:


for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.


To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.

The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website